Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title WA29330: A RANDOMIZED, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE-COMPARATOR, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RITUXIMAB VERSUS MMF IN PATIENTS WITH PEMPHIGUS VULGARIS
Description A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Study visits will be in downtown, Buffalo.
Objective To evaluate the efficacy of rituximab compared with mycophenolate mofetil (MMF) in pemphigus vulgaris

Keywords: pemphigus vulgaris, autoimmune
Principal Investigator SINHA, ANIMESH
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02383589/
Status Open
Key Eligibility Ages 18-75
Pemphigus Vulgaris
Disease Group Autoimmune Disorders; Skin/Dermatology
Treatment Mycophenolate Mofetil (MMF)
Rituximab
Contact Alba Posligua
716-645-8990
albaposl@buffalo.edu